Supportive Care Strategies for Dermatologic Toxicities Related to EGFR Inhibitor Therapies: 3-Part Knowledge Series-Session 1

Video Transcription

Video Summary

This ACCC Knowledge Series session reviews supportive care for dermatologic toxicities from EGFR inhibitors, focusing on prevention. Beth Sandy and Dr. Christine Parsegian explain EGFR-targeted therapies in non-small cell lung cancer and colorectal cancer, including common mutations, treatment options, and why these drugs often cause acneiform rash, dry skin, fissures, nail changes, scalp irritation, and eyelash overgrowth. <br /><br />In lung cancer, osimertinib generally causes less severe rash, while amivantamab/lazertinib has higher rates and benefits from proactive skin care. In colorectal cancer, cetuximab and panitumumab commonly produce significant rash, so prevention is especially important. Evidence supports preemptive oral tetracyclines such as doxycycline or minocycline, along with moisturizers, topical steroids, sunscreen, and gentle skin care. The COCOON trial showed that enhanced dermatologic management reduced rash severity with amivantamab/lazertinib. <br /><br />The speakers also discuss emerging strategies such as a topical BRAF inhibitor cream and practical measures for nail, scalp, and eye care. Overall, the message is that early prophylaxis and close monitoring help patients stay on effective EGFR therapy.

Keywords

EGFR inhibitors

dermatologic toxicities

preventive care

acneiform rash

doxycycline

amivantamab/lazertinib

cetuximab panitumumab